Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company

Refine Search
Americas
Law firm Kilpatrick Townsend & Stockton LLP has bolstered its Californian team with the appointment of a new pharmaceutical IP specialist.   12 September 2014
Big Pharma
UK-based law firm Carpmaels & Ransford LLP has announced the appointment of two new partners to its London office.   11 September 2014
Americas
Bristol-Myers Squibb has accused pharmaceutical company Merck of infringing a patent covering a method used to treat cancer.   10 September 2014
Asia-Pacific
The Australian government department responsible for IP has suggested abolishing a committee that looks after plant breeders’ rights as it looks at alternative means for giving advice to breeders.   9 September 2014
Asia-Pacific
Companies in Australia will be able to continue to patent human genes after a court rejected an appeal by a breast cancer survivor.   8 September 2014
Americas
Magistrate judge Christopher Burke has recommended that the US District Court for the District of Delaware affirm a motion to dismiss a patent infringement case related to the patent eligibility of subject matter, as laid out in 35 USC §101.   5 September 2014
article
Our expert comment this month looks at personalised medicine, but more from a business point of view than a medical one. As LSIPR readers will know, personalised medicine is all about tailoring treatment to the individual, and that, of course, can be extremely complicated.   4 September 2014
Big Pharma
For those who can draw an informative patent map and work out a good navigational route through the complexities, there is an opportunity to gain significant competitive advantages through making the right partnerships, argue Quentin Tannock and Anna Duch.   4 September 2014
Genetics
Pluristem develops therapies using cells from the placenta that have been cultured in a unique way. LSIPR finds out how the company protects and nourishes its technologies.   4 September 2014
Americas
Sifting through the published comments on the USPTO’s Myriad/Mayo guidelines, LSIPR found them to be overwhelmingly negative.   4 September 2014